Tag Archives: Andrew Fein

Analysts’ Top Healthcare Picks: BioCryst (BCRX), Crinetics Pharmaceuticals Inc (CRNX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioCryst (BCRX – Research Report), Crinetics Pharmaceuticals Inc (CRNX – Research Report) and Inovio Pharmaceuticals (INO – Research Report) with bullish sentiments.

H.C. Wainwright Reaffirms Their Buy Rating on Unum Therapeutics Inc (UMRX)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Unum Therapeutics Inc (UMRX – Research Report), with a price target of $18. The company’s shares closed yesterday at $3.21, close to its 52-week low

H.C. Wainwright Maintains a Buy Rating on Translate Bio Inc (TBIO)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Translate Bio Inc (TBIO – Research Report) today and set a price target of $21. The company’s shares closed on Friday at $9.54. Fein commented: “We remind investors that the

Corbus Pharmaceuticals (CRBP) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $24. The company’s shares closed yesterday at $6.94. Fein commented: “Valuation and risks to our investment thesis.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: MEI Pharma (NASDAQ: MEIP), Verastem (NASDAQ: VSTM) and AVEO Pharma (NASDAQ: AVEO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on MEI Pharma (MEIP – Research Report), Verastem (VSTM – Research Report) and AVEO Pharma (AVEO – Research Report). MEI Pharma (MEIP) H.C. Wainwright analyst Andrew

H.C. Wainwright Thinks Concert Pharma’s Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Concert Pharma (CNCE – Research Report), with a price target of $26. The company’s shares closed yesterday at $9.96, close to its 52-week low of